STRAIN SPECIFICITY OF ANTI-CRYPTOSPORIDIUM IGG

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$446,482.00
Award Year:
1994
Program:
SBIR
Phase:
Phase II
Contract:
n/a
Agency Tracking Number:
18926
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
Immucell Corp.
56 Evergreen Drive, Portland, ME, 04103
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
Joseph H Crabb
(207) 878-2770
Business Contact:
() -
Research Institution:
n/a
Abstract
CRYPTOSPORIDIUM PARVUM IS A SIGNIFICANT HUMAN PATHOGEN FOR WHICH NO CHEMOTHERAPY HAS BEEN SHOWN TO BE EFFICACIOUS. THE NUMBER OF CASES OF HUMAN CRYPTOSPORIDIOSIS HAS INCREASED DRAMATICALLY IN THE LAST DECADE, PARTICULARLY IN THE POPULATION OF IMMUNO-COMPROMISED INDIVIDUALS. IN THE AIDS POPULATION, THE MORTALITY RATE OF CRYPTOSPORIDIUM-INFECTED INDIVIDUALS EXCEEDS 60 PERCENT. HYPERIMMUNEANTI-CRYPTOSPORIDIUM BOVINE COLOSTRUM, HAS SHOWN AGREAT DEAL OF PROMISE IN LIMITED HUMAN STUDIES, PROVIDING THERAPEUTIC BENEFIT TO 7 OF 8 CRYPTOSPORIDIOSIS PATIENTS THUS FAR TREATED. A POSSIBLE IMPEDIMENT TO THE SUCCESSFUL DEVELOPMENT OF A CRYPTOSPORIDIUM BOVINE COLOSTRAL IMMUNOGLOBULIN PRODUCT IS THE POTENTIAL FOR ANTIGENIC DIVERSITY AMONG ISOLATES OR STRAINS OF THIS PARASITE, AS THERE IS A PAUCITY OF DATA ADDRESSING THIS ISSUE. THIS RESEARCH WILL FOCUS ON EVALUATING CROSS-REACIVITY AND CROSS- NEUTRALIZING CAPACITY AGAINST C. PARVUM ISOLATES FROM CALVES AND HUMANS AND FROM GEOGRAPHICALLYDIVERSE REGIONS USING ANTI-CRYPTOSPORIDIUM COLOSTRAL IMMUNOGLOBULIN PREPARATIONS WITH DEMONSTRATED PROTECTIVE PROPERTIES. THE LONG-TERM OBJECTIVE IS TO DISCOVER STRAINS THAT ELICIT BROAD CROSS-NEUTRALIZING ANTIBODIES FOR HUMAN THERAPEUTIC USE.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government